Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Avenue Therapeutics stock | $6.29

Own Avenue Therapeutics stock in just a few minutes.

Fact checked

Avenue Therapeutics, Inc is a biotechnology business based in the US. Avenue Therapeutics shares (ATXI) are listed on the NASDAQ and all prices are listed in US Dollars. Avenue Therapeutics employs 4 staff and has a market cap (total outstanding shares value) of USD$104.3 million.

How to buy shares in Avenue Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Avenue Therapeutics. Find the stock by name or ticker symbol: ATXI. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Avenue Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$6.29, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Avenue Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Avenue Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Avenue Therapeutics share price

Use our graph to track the performance of ATXI stocks over time.

Avenue Therapeutics shares at a glance

Information last updated 2020-12-26.
Latest market closeUSD$6.29
52-week rangeUSD$2.85 - USD$12.34
50-day moving average USD$3.8938
200-day moving average USD$8.1378
Wall St. target priceUSD$9
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.955

Buy Avenue Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Forex
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, ETFs
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Avenue Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Avenue Therapeutics price performance over time

Historical closes compared with the close of $6.29 from 2020-12-18

1 week (2021-01-15) 0.96%
1 month (2020-12-23) -1.41%
3 months (2020-10-23) 81.79%
6 months (2020-07-23) -38.57%
1 year (2020-01-23) -29.52%
2 years (2019-01-23) -1.41%
3 years (2018-01-23) 64.66%
5 years (2016-01-19) N/A

Avenue Therapeutics financials

Gross profit TTM USD$0
Return on assets TTM -66.43%
Return on equity TTM -126%
Profit margin 0%
Book value $0.193
Market capitalisation USD$104.3 million

TTM: trailing 12 months

Shorting Avenue Therapeutics shares

There are currently 345,757 Avenue Therapeutics shares held short by investors – that's known as Avenue Therapeutics's "short interest". This figure is 13% up from 306,076 last month.

There are a few different ways that this level of interest in shorting Avenue Therapeutics shares can be evaluated.

Avenue Therapeutics's "short interest ratio" (SIR)

Avenue Therapeutics's "short interest ratio" (SIR) is the quantity of Avenue Therapeutics shares currently shorted divided by the average quantity of Avenue Therapeutics shares traded daily (recently around 142286.83127572). Avenue Therapeutics's SIR currently stands at 2.43. In other words for every 100,000 Avenue Therapeutics shares traded daily on the market, roughly 2430 shares are currently held short.

However Avenue Therapeutics's short interest can also be evaluated against the total number of Avenue Therapeutics shares, or, against the total number of tradable Avenue Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Avenue Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Avenue Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.1387% of the tradable shares (for every 100,000 tradable Avenue Therapeutics shares, roughly 139 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Avenue Therapeutics.

Find out more about how you can short Avenue Therapeutics stock.

Avenue Therapeutics share dividends

We're not expecting Avenue Therapeutics to pay a dividend over the next 12 months.

Avenue Therapeutics share price volatility

Over the last 12 months, Avenue Therapeutics's shares have ranged in value from as little as $2.85 up to $12.34. A popular way to gauge a stock's volatility is its "beta".

ATXI.US volatility(beta: 0.52)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Avenue Therapeutics's is 0.5241. This would suggest that Avenue Therapeutics's shares are less volatile than average (for this exchange).

Avenue Therapeutics overview

Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was founded in 2015 and is based in New York, New York. Effective as of December 31, 2019, Avenue Therapeutics, Inc. operates as a subsidiary of InvaGen Pharmaceuticals, Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site